spacer
home > ebr > summer 2017 > editor’s letter
PUBLICATIONS
European Biopharmaceutical Review

Editor’s Letter

“It is important that rare disease businesses bring treatments to market as early as possible to give patients the best chance,” say Sobi’s Hege Hellström and Neil Dugdale in our summer 2017 industry Q&A. This captures the essence of therapy research and development for these often life-limiting illnesses affecting an estimated 70,000 patient groups. Access to the therapy, not just producing and commercialising it, should be a priority.

‘Salami-slicing’ of mass market, non-rare diseases to create artificial orphan indications is increasingly blurring lines between big pharma and specialised focus, according to The Weinberg Group’s Matthew Weinberg and Emily Krulewitz. Its driver is seemingly pharmacogenomics and the ability to stratify patients inside a group based on their genome and consequent response to particular therapies, switching them to personalised medicines.

Hermann Mascher at pharm-analyt Labor reminds us of the transformational potential these patient-specific therapeutics offer, and that particular biochemical pathways’ missing or defective components can be both the biomarker to identify a disease’s subset and the therapy to restore that deletion. If these could be characterised by bioanalytical methodologies serving a range of conditions, more synthetic forms of these endogenous small molecules may come on stream in development as therapeutics.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Deborah O’Neil, Chief Executive and Scientific Officer, NovaBiotics Ltd
spacer
Dr Deborah O’Neil
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT to Focus on the Application of In Vitro Hepatocyte Models in Toxicology Research at the North American ISSX Meeting

BioIVT, a leading provider of research models and services for drug development, today announced that it will be participating in several sessions at the 22nd North American International Society for the Study of Xenobiotics (ISSX) Meeting. This conference will be held from July 15-19 at the Palais des congrès de Montréal in Montréal, Canada.
More info >>

White Papers

Clinical Trials in Ukraine: Orange Paper Overview and 1st Half Year 2014

Synergy Research Group

The Orange Paper is an analytical report about the clinical trials market in Russia, published quarterly by the contract research organization Synergy Research Group. The first edition of Orange Paper was released in 2006, and at the moment 31 issues have already published. Now, thanks to Synergy Group Ukraine, obtaining information about the market of clinical trials in Ukraine has become possible. In Ukraine, during the period from 1996 to 2013, applicants had obtained 3,864 positive conclusions about the possibility of conducting clinical trials of drugs, both for domestic and foreign manufacturers, including conduct of multinational multi-center clinical trials (hereinafter – MMCTs)
More info >>

 
Industry Events

Pharmaceutical Packaging and Device Labelling Europe

11-12 September 2018, Munich, Germany

Relaunching the event after a three year hiatus, Pharma Packaging and Labelling Europe is back to deliver key, actionable insight on the very latest regulatory requirements, technological innovations, strategic developments, and how to implement them into your packaging and labelling chain with both maximum efficiency and minimal cost. The conference is packed with thought provoking innovative discussions.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement